Skip to main content

Table 5 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) vs. other diseases (inflammatory and non-inflammatory) of the CNS (INF and N-INF) after data reduction with PCA.

From: Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

 

Disease

Predicted Group Membershipb.c

Total

RRMS

INF and N-INF

Original

 Count

RRMS

55

14

69

INF and N-INF

11

58

69

 %

RRMS

79.7

20.3

100

INF and N-INF

15.9

84.1

100

Cross-validateda

 Count

RRMS

55

14

69

INF and N-INF

11

58

69

 %

RRMS

79.7

20.3

100

INF and N-INF

15.9

84.1

100

  1. aCross-validation is done only for those sets of samples analyzed. In cross-validation, each sample is classified by the functions derived from all samples other the one under analysis
  2. b81.9% of original grouped samples correctly classified
  3. c81.9% of cross-validated grouped samples correctly classified